54.25
price up icon1.31%   0.70
after-market Dopo l'orario di chiusura: 54.25
loading
Precedente Chiudi:
$53.55
Aprire:
$54.15
Volume 24 ore:
1.31M
Relative Volume:
0.60
Capitalizzazione di mercato:
$6.91B
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
17.96
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
-3.25%
1M Prestazione:
-8.64%
6M Prestazione:
+12.09%
1 anno Prestazione:
+5.46%
Intervallo 1D:
Value
$53.44
$54.76
Intervallo di 1 settimana:
Value
$52.73
$56.32
Portata 52W:
Value
$42.01
$70.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
Nome
Halozyme Therapeutics Inc
Name
Telefono
(858) 794-8889
Name
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
Dipendente
350
Name
Cinguettio
@halozymeinc
Name
Prossima data di guadagno
2025-02-18
Name
Ultimi documenti SEC
Name
HALO's Discussions on Twitter

Confronta HALO con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
HALO
Halozyme Therapeutics Inc
54.25 6.91B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.50 113.52B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
493.22 52.93B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
300.83 39.71B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
585.93 35.00B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.86 26.57B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2025-05-13 Downgrade Leerink Partners Market Perform → Underperform
2024-10-07 Downgrade Wells Fargo Overweight → Equal Weight
2024-09-19 Downgrade JP Morgan Overweight → Neutral
2024-06-07 Downgrade Piper Sandler Overweight → Neutral
2024-02-29 Iniziato TD Cowen Outperform
2023-07-24 Downgrade Goldman Buy → Neutral
2023-07-24 Iniziato H.C. Wainwright Buy
2023-05-10 Aggiornamento Piper Sandler Neutral → Overweight
2023-03-27 Ripresa Berenberg Buy
2023-03-16 Downgrade SVB Securities Outperform → Market Perform
2022-12-21 Ripresa Morgan Stanley Overweight
2022-11-28 Iniziato Wells Fargo Overweight
2022-09-09 Iniziato Morgan Stanley Overweight
2022-05-23 Iniziato SVB Leerink Outperform
2021-06-14 Iniziato Evercore ISI Outperform
2021-05-17 Iniziato SVB Leerink Outperform
2021-05-11 Downgrade Piper Sandler Overweight → Neutral
2021-01-21 Reiterato The Benchmark Company Buy
2020-12-17 Iniziato Berenberg Buy
2020-09-14 Ripresa JP Morgan Overweight
2020-07-01 Iniziato The Benchmark Company Buy
2020-02-05 Aggiornamento Piper Sandler Neutral → Overweight
2020-01-09 Aggiornamento BMO Capital Markets Market Perform → Outperform
2020-01-08 Iniziato Goldman Buy
2019-11-05 Aggiornamento Barclays Underweight → Equal Weight
2018-10-19 Ripresa Piper Jaffray Neutral
2018-05-11 Downgrade Barclays Equal Weight → Underweight
2018-01-24 Iniziato Goldman Neutral
2017-10-16 Reiterato Piper Jaffray Overweight
2017-01-06 Downgrade Citigroup Buy → Neutral
2016-11-03 Iniziato Deutsche Bank Buy
2015-12-04 Iniziato Wells Fargo Outperform
2015-11-18 Iniziato Citigroup Buy
2015-09-22 Iniziato Barclays Overweight
2015-06-22 Reiterato JP Morgan Overweight
2015-03-03 Reiterato UBS Buy
2015-02-18 Reiterato MLV & Co Buy
2015-01-08 Reiterato MLV & Co Buy
Mostra tutto

Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie

pulisher
11:18 AM

Merck gains U.S. patent office support in Keytruda dispute - MSN

11:18 AM
pulisher
Jun 05, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

Merck (MRK) Gains Edge in Keytruda Patent Dispute - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Merck dispute with Halozyme over Keytruda injection to get another USPTO look - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - Insider Monkey

Jun 04, 2025
pulisher
Jun 04, 2025

PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Merck granted review of Halozyme patent claims by PTAB - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme - Yahoo Finance

Jun 04, 2025
pulisher
Jun 03, 2025

Halozyme (HALO) Faces Patent Challenge as USPTO Institutes Revie - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Halozyme (HALO) Faces Patent Challenges Affecting Stock Outlook | HALO Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1 - Insider Monkey

Jun 03, 2025
pulisher
Jun 02, 2025

(HALO) Investment Report - news.stocktradersdaily.com

Jun 02, 2025
pulisher
May 31, 2025

H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN

May 31, 2025
pulisher
May 30, 2025

Halozyme to Participate at Upcoming Investor Conferences - Kilgore News Herald

May 30, 2025
pulisher
May 30, 2025

Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World

May 30, 2025
pulisher
May 29, 2025

Halozyme Therapeutics (HALO): HC Wainwright & Co. Reiterates Buy Rating | HALO Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Longview News-Journal

May 29, 2025
pulisher
May 29, 2025

Halozyme stock holds Buy rating, $72 target from H.C. Wainwright By Investing.com - Investing.com UK

May 29, 2025
pulisher
May 28, 2025

Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Halozyme CEO Sets Two Major Healthcare Conference Appearances: Goldman Sachs and Benchmark - Stock Titan

May 28, 2025
pulisher
May 28, 2025

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) - sharewise

May 28, 2025
pulisher
May 28, 2025

Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - MSN

May 28, 2025
pulisher
May 28, 2025

Implied Volatility Surging for Halozyme Therapeutics Stock Options - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

High Growth Tech Stocks To Watch In The US May 2025 - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

New Strong Buy Stocks for May 28th - The Globe and Mail

May 28, 2025
pulisher
May 18, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages - Defense World

May 18, 2025
pulisher
May 16, 2025

J&J, Halozyme cut at Leerink on price control risk for combo products - MSN

May 16, 2025
pulisher
May 16, 2025

Halozyme Therapeutics (NASDAQ:HALO) Cut to “Strong Sell” at Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 15, 2025

Halozyme downgraded at Morgan Stanley on price control risk - MSN

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Leerink Partners Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World

May 15, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concer - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Leerink Partners Downgrades Halozyme Therapeutics (BMV:HALO) - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Halozyme Therapeutics (HALO) Downgraded by Morgan Stanley | HALO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme, J&J slide as analyst cuts rating on CMS draft guidance - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded Amid Medicare Price Negotiation Conce - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ) - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

Halozyme Therapeutics downgraded by Morgan Stanley with a new price target - Quantisnow

May 14, 2025
pulisher
May 14, 2025

Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Halozyme stock holds $78 target despite Medicare concerns By Investing.com - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concerns | HALO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme stock holds $78 target despite Medicare concerns - Investing.com

May 14, 2025

Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$73.62
price up icon 1.21%
$22.20
price up icon 1.79%
$20.59
price up icon 4.36%
$33.78
price up icon 0.09%
$108.49
price down icon 1.51%
biotechnology ONC
$255.86
price down icon 0.44%
Capitalizzazione:     |  Volume (24 ore):